Clinical study of bifidobacteria triple viable bacteria capsule combined with quadruple therapy in treatment of HP positive gastric ulcer was written by Li, Huan-qun. And the article was included in Xiandai Zhenduan Yu Zhiliao in 2021.Recommanded Product: 117976-90-6 The following contents are mentioned in the article:
Objective: To investigate the therapeutic effect of Bifidobacterium triple viable bacteria capsule combined with quadruple therapy on Helicobacter pylori (HP) pos. gastric ulcer (SU). Methods: A total of 50 HP-pos. SU patients admitted to our hospital from Jan. 2019 to Oct. 2020 were selected and divided into the control group and the observation group with 25 cases in each group by tossing a coin method. The control group was given quadruple therapy, and the observation group was given Bifidobacterium triple viable capsules orally on the basis of the control group. The curative effect, HP neg. rate and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, 44 cases of HP in the observation group turned neg., and the neg. conversion rate was 89.80%. In the control group, HP turned neg. in 33 cases, and the neg. conversion rate was 68.75%. There was a statistically significant difference between the two groups (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Bifidobacterium triple viable bacteria capsule combined with quadruple therapy is effective in the treatment of HP pos. SU, which can improve the HP neg. conversion rate and has good safety. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: 117976-90-6).
Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Recommanded Product: 117976-90-6
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem